- Home
- OMER vs SRG Comparison
OMER vs SRG Comparison
Compare OMER & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- SRG
- Stock Information
- Founded
- OMER 1994
- SRG 2014
- Country
- OMER United States
- SRG United States
- Employees
- OMER N/A
- SRG N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- SRG Real Estate Investment Trusts
- Sector
- OMER Health Care
- SRG Real Estate
- Exchange
- OMER Nasdaq
- SRG Nasdaq
- Market Cap
- OMER 188.1M
- SRG 163.3M
- IPO Year
- OMER 2009
- SRG 2015
- Fundamental
- Price
- OMER $3.65
- SRG $3.05
- Analyst Decision
- OMER Strong Buy
- SRG
- Analyst Count
- OMER 5
- SRG 0
- Target Price
- OMER $18.00
- SRG N/A
- AVG Volume (30 Days)
- OMER 936.6K
- SRG 92.7K
- Earning Date
- OMER 08-06-2025
- SRG 08-13-2025
- Dividend Yield
- OMER N/A
- SRG N/A
- EPS Growth
- OMER N/A
- SRG N/A
- EPS
- OMER N/A
- SRG N/A
- Revenue
- OMER N/A
- SRG N/A
- Revenue This Year
- OMER N/A
- SRG N/A
- Revenue Next Year
- OMER $468.75
- SRG N/A
- P/E Ratio
- OMER N/A
- SRG N/A
- Revenue Growth
- OMER N/A
- SRG N/A
- 52 Week Low
- OMER $2.95
- SRG $2.43
- 52 Week High
- OMER $13.60
- SRG $5.52
- Technical
- Relative Strength Index (RSI)
- OMER 54.74
- SRG 58.29
- Support Level
- OMER $3.00
- SRG $2.94
- Resistance Level
- OMER $3.25
- SRG $3.18
- Average True Range (ATR)
- OMER 0.24
- SRG 0.11
- MACD
- OMER 0.10
- SRG 0.01
- Stochastic Oscillator
- OMER 83.33
- SRG 78.13
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.